Stocktwits Top 25 – Week 34 📈

ST Top 25 S&P 500

The ST Top 25 S&P 500 List rallied in Week 34.

23 out of 25 names closed positive.

Devon Energy accelerated 18.1% to become the best performer. The energy company can be found on the Winners list below.

Moderna and West Pharma Services were the laggards. $MRNA tumbled 0.20% and $WST spilled 0.57%.

Four Freshmen debuted: $ALB, $GS, $FANG, and $AMAT.

The Stocktwits Top 25 S&P 500 Momentum Meter increased 5.23% while the S&P 500 gained 1.52%. The 3.71% differential in favor of the top stocks shows the full index lagged.

ST Top 25 Nasdaq 100

The ST Top 25 N100 trended higher. 📈

20 names traded higher. 

NXPI Semiconductors N.V. hitched a ride to #10 on the large-cap list this week, rising 10.4%. Peep $NXPI in the Winners section. 👀

O’Reilly Automotive sputtered in Week 34. $ORLY dropped 2.4%, dropping to #22 on the list.

KLA Corp, Lam Research Corp, and Synopsys Inc are the Freshmen.

The ST Top 25 Nasdaq 100 Momentum Meter moved up 3.2% in Week 34 while the full Nasdaq 100 increased 2.26%. The 0.94% difference shows the top stocks were stronger than the full index.

ST Top 25 Russell 2000

The ST Top 25 R2K List added the most gains in Week 34.

22 of 25 names traded positive. 

Cassava Sciences lost bigly this week. $SAVA plunged 43.9% and earned a spot as a Sinner.

Dynavax Technologies released its Covid-19 vaccine in Taiwan this week, helping it weasel up the ST Top 25 R2K leaderboard. Check out the Top Dawg below.

$AMC ascended 18.7%, $TTI scaled 25.8% and $CDEV catapulted 24.8%. 

This week’s Freshmen are $DVAX, $CDEV, $PAVM, and $SB.

The ST Top 25 R2K Momentum Meter ripped 11.92% and the Russell 2000 index expanded 5.05%. The 6.87% differential proves the top stocks were far stronger than the full index.

ST Top 25 TOP DAWG OF THE WEEK 🐶

The ST Top 25 Top Dawg for Week 34, 2021 is #16 R2K – Dynavax Technologies. 

Dynavax Technologies increased 40.4% in Week 34 and entered the ST Top 25 R2K List as a Freshman. It entered as #16 on the list.

Shares of the biotech soared 14.4% on Monday after announcing the rollout of its COVID-19 vaccine in Taiwan. The company indicated that around 600,000 people were expected to receive the vaccine this week.

$DVAX closed at three-year highs, here’s the daily chart:

$DVAX is up 280% YTD.

The Winners 📈

△ #6 S&P 500 – Devon Energy had itself one helluva week. The energy company climbed 18.1% and improved five spots from #11 to #6 on the ST Top 25 S&P 500 List.

$DVN closed green four out of five days this week as the Energy ETF $XLE recouped nearly all of Week 33’s losses.

Here’s the weekly chart:

$DVN is up 92% YTD.

△ #10 N100 – NXP Semiconductors N.V. was the top-performing stock on the ST Top 25 N100 List. $NXPI spiked 10.5% and ascended from #20 to #10.

$NXPI traded positive everyday this week. The semi went on a complete tear, closing at all-time highs on Friday. 

On Monday, the company’s board of directors approved the payment of an interim dividend. They also announced an increase to the company’s share repurchase authorization. The measures are based on the board’s belief in NXP’s capacity to deliver long-term growth and robust cash flow, as well as the capital structure’s substantial strength.

$NXPI is up 42.45% YTD.

△ #19 R2K – Tetra Technologies gained some traction in Week 34. The electronic component distributor was the second biggest gainer on the ST Top 25 R2K List, just behind Dynavax Tech.

$TTI popped 12.9% on Monday, coasted Tuesday through Thursday, and tacked on another 15% on Friday. 

Here is this week’s 15-minute chart:

$TTI is now up 273.8% YTD.

The Sinners 📉

▼ #22 N100 – O’Reilly Automotive fell the furthest on the ST Top 25 N100 List in Week 34. $ORLY lost 2.4% and moved seven spots lower.

$ORLY chopped around for most of the week before falling 1.4% on Friday.

The stock found support at its 50-day moving average, we’ll see if it holds in the week to come.

$ORLY is still up 30.8% YTD.

▼ #2 R2K – Cassava Sciences had its worst week in over a year, losing 43.9%. The biotech remains in the #2 spot on the ST Top 25 R2K List, trailing AMC Entertainment. 

$SAVA sank 31.4% on Wednesday after a Citizen Petition was filed with the US Food and Medication Administration, seeking that two current studies for Cassava’s Alzheimer’s drug be halted. According to the Citizen Petition, Cassava’s usage of Simufilam is based on widespread data manipulation and deception.

Cassava Sciences responded by saying the company stands by its research, its scientists, and its scientific colleagues, and is taking steps to ensure that the facts are understood and appreciated.

Remi Barbier, President & CEO: 

“As a science company, we champion facts that can be evaluated and verified. This helps people make informed choices. It is important for stakeholders to separate fact from fiction, which is why we wish to address allegations head-on.”

$SAVA is up 60.7% YTD.